Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...